CoChat
Sign Up
Cited by 60

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies

Pardeo, Manuela, Bracaglia, Claudia, De Benedetti, Fabrizio·2017·Best Practice & Research Clinical Rheumatology
DOI 10.1016/j.berh.2018.02.002
Open this paper in CoChat — free account

Abstract

Systemic juvenile idiopathic arthritis (sJIA) is considered as a polygenic autoinflammatory disease. The prominent systemic clinical features, the marked elevation of inflammatory markers, and the absence of autoantibodies make this disease very different from the other juvenile idiopathic arthritis (JIA) forms. Innate immune mechanisms appear to play a central role: the overproduction of inflammatory cytokines of innate immunity is a typical feature of sJIA. Increased understanding of the role of these cytokines has been translated into therapeutic approaches. Indeed, remarkable results have been observed with interleukin-1 (IL-1) and interleukin-6 (IL-6) inhibitors both in clinical trials and in real life. Other inhibitors of these cytokines will be available in the near future, thereby increasing the therapeutic armamentarium. A better understanding of the pathophysiology of sJIA is still needed to identify IL-1 or IL-6 responders, define a potential window of opportunity for early cytokine blockade, and identify a targeted treatment for macrophage activation syndrome. Additional therapeutic targets are needed for a small proportion of patients who do not respond to either IL-1 or IL-6 inhibition.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.berh.2018.02.002

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 79

  1. Ravelli, 2007, Juvenile idiopathic arthritis, Lancet, 369, 767, 10.1016/S0140-6736(07)60363-8 · DOI
  2. Masters, 2009, Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease, Annu Rev Immunol, 27, 621, 10.1146/annurev.immunol.25.022106.141627 · DOI
  3. Martini, 2012, Systemic juvenile idiopathic arthritis, Autoimmun Rev, 12, 56, 10.1016/j.autrev.2012.07.022 · DOI
  4. Hedrich, 2013, Bridging the gap between autoinflammation and autoimmunity, Clin Immunol, 147, 151, 10.1016/j.clim.2013.03.006 · DOI
  5. Ravelli, 2012, Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment, Genes Immun, 13, 289, 10.1038/gene.2012.3 · DOI
  6. Behrens, 2007, Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis, J Rheumatol, 34, 1133
  7. Petty, 2004, International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001, J Rheumatol, 31, 390
  8. Schneider, 1998, Systemic onset juvenile rheumatoid arthritis, Bailliere’s Clin Rheumatol, 12, 245, 10.1016/S0950-3579(98)80018-6 · DOI
  9. Lang, 1995, Radiologic features of systemic onset juvenile rheumatoid arthritis, J Rheumatol, 22, 168
  10. Martini, 2012, It is time to rethink juvenile idiopathic arthritis classification and nomenclature, Ann Rheum Dis, 71, 1437, 10.1136/annrheumdis-2012-201388 · DOI
  11. Ogilvie, 2003, The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families, Arthritis Rheum, 48, 3202, 10.1002/art.11300 · DOI
  12. De Benedetti, 2003, British Paediatric Rheumatology Study Group. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 48, 1398, 10.1002/art.10882 · DOI
  13. Stock, 2008, Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis, Genes Immun, 9, 349, 10.1038/gene.2008.24 · DOI
  14. Ombrello, 2015, HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis, Proc Natl Acad Sci USA, 112, 15970, 10.1073/pnas.1520779112 · DOI
  15. Ombrello, 2017, Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications, Ann Rheum Dis, 76, 906, 10.1136/annrheumdis-2016-210324 · DOI
  16. Barnes, 2009, Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiophathic arthritis, Arthritis Rheum, 6D, 2102, 10.1002/art.24601 · DOI
  17. Allantz, 2007, Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade, J Exp Med, 204, 2131, 10.1084/jem.20070070 · DOI
  18. Ishikawa, 2009, Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis, Ann Rheum Dis, 68, 264, 10.1136/ard.2007.079533 · DOI
  19. Mellins, 2011, Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions, Nat Rev Rheumatol, 7, 416, 10.1038/nrrheum.2011.68 · DOI
  20. Sandborg, 2012, A new era in the treatment of systemic juvenile idiopathic arthritis, N Engl J Med, 367, 2430, 10.1056/NEJMe1212640 · DOI
  21. Pascual, 2005, Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade, J Exp Med, 201, 1479, 10.1084/jem.20050473 · DOI
  22. Dinarello, 1996, Biologic basis for interleukin-1 in disease, Blood, 87, 2095, 10.1182/blood.V87.6.2095.bloodjournal8762095 · DOI · Paper page
  23. Ruperto, 2012, Two randomized trials of Canakinumab in systemic juvenile idiopathic arthritis, N Engl J Med, 367, 2396, 10.1056/NEJMoa1205099 · DOI
  24. De Benedetti, 1991, Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis, Arthritis Rheum, 34, 1158, 10.1002/art.1780340912 · DOI · Paper page
  25. De Benedetti, 2006, Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system, Arthritis Rheum, 54, 3551, 10.1002/art.22175 · DOI · Paper page
  26. Caiello, 2014, IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases, PLoS One, 9, e107886, 10.1371/journal.pone.0107886 · DOI
  27. De Benedetti, 2012, Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis, N Engl J Med, 367, 2385, 10.1056/NEJMoa1112802 · DOI · Paper page
  28. Kessel, 2013, Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers, Clin Immunol, 147, 229, 10.1016/j.clim.2012.11.008 · DOI
  29. Frosch, 2009, The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 60, 883, 10.1002/art.24349 · DOI
  30. Swart, 2016, Understanding inflammation in juvenile idiopathic arthritis: How immune biomarkers guide clinical strategies in the systemic onset subtype, Eur J Immunol, 46, 2068, 10.1002/eji.201546092 · DOI
  31. Holzinger, 2012, The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis, Ann Rheum Dis, 71, 974, 10.1136/annrheumdis-2011-200598 · DOI
  32. Okamura, 1995, A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock, Infect Immun, 63, 3966, 10.1128/iai.63.10.3966-3972.1995 · DOI
  33. Okamura, 1995, Cloning of a new cytokine that induces IFN-g production by T cells, Nature, 378, 88, 10.1038/378088a0 · DOI
  34. Leung, 2001, A role for IL-18 in neutrophil activation, J Immunol, 167, 2879, 10.4049/jimmunol.167.5.2879 · DOI
  35. Maeno, 2002, Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima, et al, Arthritis Rheum, 46, 2539, 10.1002/art.10389 · DOI
  36. Jelusić, 2007, Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis, Clin Rheumatol, 26, 1332, 10.1007/s10067-006-0474-0 · DOI
  37. Shimizu, 2015, Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis, Clin Immunol, 160, 277, 10.1016/j.clim.2015.06.005 · DOI
  38. Bracaglia, 2017, Biomarkers for the diagnosis and the identification of risk of macrophage activation syndrome (MAS) in systemic juvenile idiopathic arthritis (sJIA), Arthritis Rheumatol, 69
  39. Canna, 2014, An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome, Nat Genet, 46, 1140, 10.1038/ng.3089 · DOI
  40. Romberg, 2014, Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation, Nat Genet, 46, 1135, 10.1038/ng.3066 · DOI
  41. Grom, 2003, Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome, J Pediatr, 142, 292, 10.1067/mpd.2003.110 · DOI
  42. Cifaldi, 2014, Inhibition of natural killer (nk) cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome, Pediatr Rheumatol, 12, 56, 10.1186/1546-0096-12-S1-P56 · DOI
  43. de Jager, 2009, Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 60, 2782, 10.1002/art.24750 · DOI
  44. Vastert, 2010, Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis, Rheumatology (Oxford), 49, 441, 10.1093/rheumatology/kep418 · DOI
  45. Zhang, 2008, Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms, Arthritis Rheum, 58, 2892, 10.1002/art.23734 · DOI
  46. Hazen, 2008, Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis, Arthritis Rheum, 58, 567, 10.1002/art.23199 · DOI
  47. Bracaglia, 2014, Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occurring in systemic juvenile idiopathic arthritis (sJIA), Pediatr Rheumatol Online J, 12, 53, 10.1186/1546-0096-12-S1-P53 · DOI
  48. Strippoli, 2013, Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome, J Rheumatol, 40, 761, 10.3899/jrheum.121233 · DOI
  49. Boom, 2015, Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis, Pediatr Rheumatol Online J, 13, 55, 10.1186/s12969-015-0055-3 · DOI
  50. Nigrovic, 2011, Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series, Arthritis Rheum, 63, 545, 10.1002/art.30128 · DOI
  51. Grom, 2016, Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab, Arthritis Rheumatol, 68, 218, 10.1002/art.39407 · DOI
  52. Ravelli, 2014, A56: macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab, Arthritis Rheumatol, S83
  53. Yokota, 2015, Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab, J Rheumatol, 42, 712, 10.3899/jrheum.140288 · DOI
  54. Jordan, 2004, An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder, Blood, 104, 735, 10.1182/blood-2003-10-3413 · DOI · Paper page
  55. Pachlopnik Schmid, 2009, Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice, EMBO Mol Med, 1, 112, 10.1002/emmm.200900009 · DOI
  56. Takada, 2003, Increased serum levels of interferongamma-iinducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis, Clin Exp Immunol, 133, 448, 10.1046/j.1365-2249.2003.02237.x · DOI
  57. Xu, 2012, Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children, J Pediatr, 160, 984, 10.1016/j.jpeds.2011.11.046 · DOI
  58. Bracaglia, 2017, Elevated circulating levels of interferon-γ and interferon-γ induced chemokines characterize patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis, Ann Rheum Dis, 76, 166, 10.1136/annrheumdis-2015-209020 · DOI
  59. Prencipe, 2017, Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome, J Allergy Clin Immunol, 12, S0091
  60. Quartier, 2011, A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial), Ann Rheum Dis, 70, 747, 10.1136/ard.2010.134254 · DOI
  61. Ilowite, 2014, Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis, Arthritis Rheumatol, 66, 2570, 10.1002/art.38699 · DOI
  62. Yokota, 2008, Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial, Lancet, 371, 998, 10.1016/S0140-6736(08)60454-7 · DOI · Paper page
  63. Vastert, 2014, Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study, Arthritis Rheumatol, 66, 1034, 10.1002/art.38296 · DOI
  64. Pardeo, 2015, Anakinra in systemic juvenile idiopathic arthritis: a single-center experience, J Rheumatol, 42, 1523, 10.3899/jrheum.141567 · DOI
  65. Gattorno, 2008, A. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 58, 1505, 10.1002/art.23437 · DOI
  66. Lequerré, 2008, Ann Rheum Dis, 67, 302, 10.1136/ard.2007.076034 · DOI
  67. Verbsky, 2004, Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis, J Rheumatol, 31, 2071
  68. Urien, 2013, Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoimflammatory syndromes, BMC Pharmacol and Toxicol, 14, 40, 10.1186/2050-6511-14-40 · DOI
  69. Yokota, 2016, Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan, Ann Rheum Dis, 75, 1654, 10.1136/annrheumdis-2015-207818 · DOI
  70. Grom, 2016, Macrophage activation syndrome in the era of biologic therapy, Nat Rev Rheumatol, 12, 259, 10.1038/nrrheum.2015.179 · DOI
  71. Schulert, 2017, Biologic therapy modifies clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis, Arthritis Care Res (Hoboken)
  72. Ravelli, 2016, Ann Rheum Dis, 75, 481, 10.1136/annrheumdis-2015-208982 · DOI
  73. DeWitt, 2012, Juvenile idiopathic arthritis disease-specific research committee of childhood arthritis rheumatology and research alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis, Arthritis Care Res, 64, 1001, 10.1002/acr.21625 · DOI
  74. Ringold, 2013, Arthritis Care Res, 65, 1551, 10.1002/acr.22087 · DOI
  75. Nigrovic, 2014, Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?, Arthritis Rheumatol, 66, 1405, 10.1002/art.38615 · DOI
  76. Tarp, 2016, Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials, Rheumatology, 554, 669, 10.1093/rheumatology/kev382 · DOI
  77. Kessel, 2017, Proinflammatory cytokine environments can drive Interleukin-17 overexpression by γ/δ T cells in systemic juvenile idiopathic arthritis, Arthritis Rheumatol, 69, 1480, 10.1002/art.40099 · DOI
  78. Jordan, 2015, A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI-0501: first results from a pilot Phase 2 study in children with primary HLH, Blood, 126, 10.1182/blood.V126.23.LBA-3.LBA-3 · DOI
  79. Bracaglia, 2015, Anti-interferon-gamma (IFNγ) monoclonal antibody treatment in a child with NLRC4-related disease and severe hemophagocytic lymphohistiocytosis (HLH), Arthritis Rheumatol, 67

Cited by

Sorted by citations

See all 60

Metadata

Authors
Pardeo, M., Bracaglia, C., & De Benedetti, F.
Venue
Best Practice & Research Clinical Rheumatology
Publisher
Elsevier BV
Published
2017-08
Volume
31
Issue
4
Pages
505-516
ISSN
1521-6942
DOI
10.1016/j.berh.2018.02.002
Cited by
60
References
6
Language
en
Licence
Funders
  • Gilead Sciences
  • AbbVie
  • Sanofi

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review